236 related articles for article (PubMed ID: 30459812)
1. Macrophage Depletion in Elderly Mice Improves Response to Tumor Immunotherapy, Increases Anti-tumor T Cell Activity and Reduces Treatment-Induced Cachexia.
Duong L; Radley-Crabb HG; Gardner JK; Tomay F; Dye DE; Grounds MD; Pixley FJ; Nelson DJ; Jackaman C
Front Genet; 2018; 9():526. PubMed ID: 30459812
[TBL] [Abstract][Full Text] [Related]
2. Targeting macrophages rescues age-related immune deficiencies in C57BL/6J geriatric mice.
Jackaman C; Radley-Crabb HG; Soffe Z; Shavlakadze T; Grounds MD; Nelson DJ
Aging Cell; 2013 Jun; 12(3):345-57. PubMed ID: 23442123
[TBL] [Abstract][Full Text] [Related]
3. The Regulatory Status Adopted by Lymph Node Dendritic Cells and T Cells During Healthy Aging Is Maintained During Cancer and May Contribute to Reduced Responses to Immunotherapy.
Gardner JK; Jackaman C; Mamotte CDS; Nelson DJ
Front Med (Lausanne); 2018; 5():337. PubMed ID: 30560130
[TBL] [Abstract][Full Text] [Related]
4. Aging Leads to Increased Monocytes and Macrophages With Altered CSF-1 Receptor Expression and Earlier Tumor-Associated Macrophage Expansion in Murine Mesothelioma.
Duong L; Pixley FJ; Nelson DJ; Jackaman C
Front Aging; 2022; 3():848925. PubMed ID: 35821822
[TBL] [Abstract][Full Text] [Related]
5. IL-2/CD40-activated macrophages rescue age and tumor-induced T cell dysfunction in elderly mice.
Jackaman C; Dye DE; Nelson DJ
Age (Dordr); 2014 Jun; 36(3):9655. PubMed ID: 24744051
[TBL] [Abstract][Full Text] [Related]
6. Murine mesothelioma induces locally-proliferating IL-10(+)TNF-α(+)CD206(-)CX3CR1(+) M3 macrophages that can be selectively depleted by chemotherapy or immunotherapy.
Jackaman C; Yeoh TL; Acuil ML; Gardner JK; Nelson DJ
Oncoimmunology; 2016 Jun; 5(6):e1173299. PubMed ID: 27471652
[TBL] [Abstract][Full Text] [Related]
7. Are macrophages, myeloid derived suppressor cells and neutrophils mediators of local suppression in healthy and cancerous tissues in aging hosts?
Jackaman C; Nelson DJ
Exp Gerontol; 2014 Jun; 54():53-7. PubMed ID: 24291067
[TBL] [Abstract][Full Text] [Related]
8. CD8
Jackaman C; Gardner JK; Tomay F; Spowart J; Crabb H; Dye DE; Fox S; Proksch S; Metharom P; Dhaliwal SS; Nelson DJ
Oncoimmunology; 2019; 8(4):e1564452. PubMed ID: 30906657
[TBL] [Abstract][Full Text] [Related]
9. Nanoliposome C6-Ceramide Increases the Anti-tumor Immune Response and Slows Growth of Liver Tumors in Mice.
Li G; Liu D; Kimchi ET; Kaifi JT; Qi X; Manjunath Y; Liu X; Deering T; Avella DM; Fox T; Rockey DC; Schell TD; Kester M; Staveley-O'Carroll KF
Gastroenterology; 2018 Mar; 154(4):1024-1036.e9. PubMed ID: 29408569
[TBL] [Abstract][Full Text] [Related]
10. IL-2/CD40-driven NK cells install and maintain potency in the anti-mesothelioma effector/memory phase.
Jackaman C; Lansley S; Allan JE; Robinson BW; Nelson DJ
Int Immunol; 2012 Jun; 24(6):357-68. PubMed ID: 22354912
[TBL] [Abstract][Full Text] [Related]
11. The STING agonist, DMXAA, reduces tumor vessels and enhances mesothelioma tumor antigen presentation yet blunts cytotoxic T cell function in a murine model.
Graham PT; Nowak AK; Cornwall SMJ; Larma I; Nelson DJ
Front Immunol; 2022; 13():969678. PubMed ID: 36466911
[TBL] [Abstract][Full Text] [Related]
12. B-cell depletion using an anti-CD20 antibody augments antitumor immune responses and immunotherapy in nonhematopoetic murine tumor models.
Kim S; Fridlender ZG; Dunn R; Kehry MR; Kapoor V; Blouin A; Kaiser LR; Albelda SM
J Immunother; 2008 Jun; 31(5):446-57. PubMed ID: 18463540
[TBL] [Abstract][Full Text] [Related]
13. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines.
Zitvogel L; Mayordomo JI; Tjandrawan T; DeLeo AB; Clarke MR; Lotze MT; Storkus WJ
J Exp Med; 1996 Jan; 183(1):87-97. PubMed ID: 8551248
[TBL] [Abstract][Full Text] [Related]
14. Aging predisposes to acute inflammatory induced pathology after tumor immunotherapy.
Bouchlaka MN; Sckisel GD; Chen M; Mirsoian A; Zamora AE; Maverakis E; Wilkins DE; Alderson KL; Hsiao HH; Weiss JM; Monjazeb AM; Hesdorffer C; Ferrucci L; Longo DL; Blazar BR; Wiltrout RH; Redelman D; Taub DD; Murphy WJ
J Exp Med; 2013 Oct; 210(11):2223-37. PubMed ID: 24081947
[TBL] [Abstract][Full Text] [Related]
15.
Bamodu OA; Kuo KT; Wang CH; Huang WC; Wu ATH; Tsai JT; Lee KY; Yeh CT; Wang LS
Nutrients; 2019 Sep; 11(10):. PubMed ID: 31547048
[TBL] [Abstract][Full Text] [Related]
16. Anti-PD-L1 Treatment Results in Functional Remodeling of the Macrophage Compartment.
Xiong H; Mittman S; Rodriguez R; Moskalenko M; Pacheco-Sanchez P; Yang Y; Nickles D; Cubas R
Cancer Res; 2019 Apr; 79(7):1493-1506. PubMed ID: 30679180
[TBL] [Abstract][Full Text] [Related]
17. The efficacy of tumor debulking surgery is improved by adjuvant immunotherapy using imiquimod and anti-CD40.
Khong A; Cleaver AL; Fahmi Alatas M; Wylie BC; Connor T; Fisher SA; Broomfield S; Lesterhuis WJ; Currie AJ; Lake RA; Robinson BW
BMC Cancer; 2014 Dec; 14():969. PubMed ID: 25518732
[TBL] [Abstract][Full Text] [Related]
18. IL-2 intratumoral immunotherapy enhances CD8+ T cells that mediate destruction of tumor cells and tumor-associated vasculature: a novel mechanism for IL-2.
Jackaman C; Bundell CS; Kinnear BF; Smith AM; Filion P; van Hagen D; Robinson BW; Nelson DJ
J Immunol; 2003 Nov; 171(10):5051-63. PubMed ID: 14607902
[TBL] [Abstract][Full Text] [Related]
19. Effector cells of low-dose IL-2 immunotherapy in tumor bearing mice: tumor cell killing by CD8+ cytotoxic T lymphocytes and macrophages.
Maas RA; Roest PA; Becker MJ; Weimar IS; Dullens HF; Den Otter W
Immunobiology; 1992 Nov; 186(3-4):214-29. PubMed ID: 1490728
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of experimental cancer cachexia. Interaction between mononuclear phagocytes and colon-26 carcinoma and its relevance to IL-6-mediated cancer cachexia.
Strassmann G; Jacob CO; Evans R; Beall D; Fong M
J Immunol; 1992 Jun; 148(11):3674-8. PubMed ID: 1534101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
